BENSALEM, Pa., Sept. 26, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA). IF YOU ARE AN INVESTOR WHO...
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) investors of the November 7, 2025 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Savara securities between March 7, 2024 through May 23, 2025 (“the Class Period”). Follow the link below for more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened? On May 27, 2025, Savara issued a press release “an
(NASDAQ:SVRA) BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES F
(NASDAQ:SVRA) LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class Action
(NASDAQ:SVRA) BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). Savara investors have until November 7, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE
(NASDAQ:SVRA) LOS ANGELES--(BUSINESS WIRE)---- $SVRA--SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
(NASDAQ:SVRA) BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ho
(NASDAQ:SVRA) LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SAVARA (SVRA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On May 27, 2025, Savara issue
(NASDAQ:SVRA) LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SAVARA (SVRA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 27, 2025, Savara issued a press release announcing that the U.S. Food and Drug A
(NASDAQ:SVRA) NEW YORK--(BUSINESS WIRE)---- $SVRA #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) and reminds investors of the November 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has re
(NASDAQ:SVRA) NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) securities during the period of March 7, 2024 through May 23, 2025, inclusive (“the Class Period”). If you suffered a loss on your Savara investments, you have until November 7, 2025 to request lead plaintiff appointment. Follow the link below for more information: [CONTACT THE FIRM IF YOU SU
(NASDAQ:SVRA) LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the “Company”) (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced an increased estimate of autoimmune PAP diagnosed prevalence in the U.S. The updated analysis indicates an ~50% larger autoimmune PAP patient population in the U.S. than the Company’s previously estimated claims analysis from 2023 (~5,500 autoimmune PAP patients versus ~3,600). The recent analysis of health claims data was
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at two upcoming healthcare conferences. Wells Fargo Securities Healthcare Conference September 3, 2025, 4:30pm ET/1:30pm PT H.C. Wainwright Global Healthcare Conference September 9, 2025, 1:00pm ET/10:00am PT The live webcasts and subsequent replays will be a
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled “A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis” will appear in the August 21, 2025, online version of the publication and can be found at www.nejm.org. Following the onlin
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the European Respiratory Society (ERS) Congress 2025, September 27 – October 1, Amsterdam, The Netherlands. The Company will also host an Industry Evening Mini Symposium titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis” at the meeting. ERS Congress 2025
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2025 and provided a business update. “Following a recent Type A meeting with the FDA, and receipt of the meeting minutes, we believe we have aligned on a path forward for the information needed to resubmit the BLA with Fujifilm as our drug substance manufacturer,” said Matt Pa
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Savara's Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit in Q4 2025.
